Responsive image

 首頁 |   Language  : English


健康科學學院 > 醫學研究所 > 期刊論文 >

題名:Arsenic compounds activate the MAPK and caspase pathways to induce apoptosis in OEC‑M1 gingival epidermal carcinoma
作者:Foo NP, Ko CL, Chu CY, Wang CY, So EC and Huang BM
發表頁數:pp. 2701-2714
摘要:Abstract. Arsenic is a well-documented environmental toxicant that can induce neurotoxicity and peripheral vascular diseases. In fact, arsenic trioxide has been used to treat various cancer types. Oral cancer has been in the top ten common cancers for decades in Taiwan, and the incidence rate is continuously increasing. The majority of oral cancers are associated with excessive tobacco, alcohol consumption and betel chewing. To the best of our knowledge, no study has revealed the effect of arsenic compounds on oral cancers. Thus, the present study used OEC-M1 oral squamous carcinoma cells treated with sodium arsenite (NaAsO2) and dimethylarsenic acid (DMA) to determine whether both arsenic compounds could exert anticancer effects on oral cancer. The results demonstrated that NaAsO2 and DMA induced rounding up and membrane blebbing in OEC-M1 cells, which are morphological characteristics of apoptosis. Annexin V/PI double staining analysis further confirmed that both arsenic compounds induced apoptosis of OEC-M1 cells. In addition, NaAsO2 and DMA significantly decreased the survival rate and increased the percentage of OEC-M1 cells in the subG1 and G2/M phases (P<0.05). Furthermore, both arsenic compounds significantly activated the cleavage of caspase-8, -9, -3 and PARP, and the phosphorylation of JNK, ERK1/2 and p38 in OEC-M1 cells (P<0.05). Collectively, the findings of the present study indicated that NaAsO2 and DMA stimulate extrinsic and intrinsic apoptotic pathways through the activation of the MAPK pathways to induce apoptosis of OEC-M1 cells, suggesting that NaAsO2 and DMA may be used as novel anticancer drugs for oral cancers
英文關鍵字:sodium arsenite, dimethylarsenic acid, oral cancer, OEC-M1, apoptosis, caspase pathway, MAPK pathway
DOI: DOI:10.3892/or.2020.7793